



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

DIVISION OF  
CORPORATION FINANCE

July 25, 2023

Michael Henderson, M.D.  
Chief Executive Officer  
Apogee Therapeutics, Inc.  
221 Crescent St., Building 17, Suite 102b  
Waltham, MA 02453

**Re: Apogee Therapeutics, Inc.  
Amendment No. 2 to Registration Statement on Form S-1  
Exhibit Nos. 10.5, 10.7, 10.9, 10.10, 10.11 and 10.12  
Filed July 10, 2023  
File No. 333-272831**

Dear Michael Henderson:

We have concluded our assessment of your redacted exhibits for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance